Real world utilization of 91 day extended levonorgestrel-containing combined oral contraceptives in Europe: a multinational database study

Sigal Kaplan; Massoud Toussi; Alison Evans; Sandeep Dhanda; Debabrata Roy; Amir Lass

doi:10.6084/m9.figshare.13587720.v1

Back

Real world utilization of 91 day extended levonorgestrel-containing combined oral contraceptives in Europe: a multinational database study

Journal article

Open access

Peer reviewed

Real world utilization of 91 day extended levonorgestrel-containing combined oral contraceptives in Europe: a multinational database study

Sigal Kaplan, Massoud Toussi, Alison Evans, Sandeep Dhanda, Debabrata Roy and Amir Lass

Current medical research and opinion, v 37(3)

10 Feb 2021

DOI: https://doi.org/10.6084/m9.figshare.13587720.v1

PMID: 33459071

Featured in Collection : UN Sustainable Development Goals @ Drexel

Files and links (1)

url

https://doi.org/10.6084/m9.figshare.13587720.v1View

Preprint (Author's original)Open Access (License Unspecified), Open

Abstract

cardiovascular system & hematology

clinical medicine

Combined oral contraceptives

Database study

Drug Utilization

general & internal medicine

Levonorgestrel

medical and health sciences

Medical emergency

Multinational corporation

Real world data

Risk management plan

Seasonique

Objective: As part of the risk management plan in Europe, this study was conducted to characterize drug utilization patterns of Seasonique, a 91-day extended levonorgestrel-containing combined oral contraceptive (COCLNG). Methods: A retrospective observational study was conducted in France, Italy and Belgium using electronic medical record databases obtained from general practitioners (GPs) in all participating countries and gynecologists in France from 2015-2018. The study population included women receiving ≥1 prescription of 91-day COCLNG during the study period. Prescribing patterns of 91-day COCLNG were examined including: (1) treatment duration; (2) indication; (3) use of combined oral contraceptive (COC) before 91-day COCLNG initiation; and (4) switch from and to combined hormonal contraceptives (CHC) or other contraceptives. Results: A total of 235, 220, 207 and 659 women using 91-day COCLNG were identified in French, Italian and Belgian GP and French gynecologist databases, respectively. Across databases, 46%-76% of women were prescribed a single 91-day COCLNG prescription and median treatment duration ranged from 3-6 months. The most common indication was contraception (42%-81%), followed by menstrual migraines (2%-14%). Use of COC during the six months prior to 91-day COCLNG initiation was 14% across GP databases, but was lower (8%) in the French gynecologist database. The frequency of switching from 91-day COCLNG to CHCs or other contraceptives was generally low (5%-12%), with the highest proportion being among patients of French gynecologists. Conclusions: Findings indicate that 91-day COCLNG was prescribed for relatively short durations and predominantly as indicated for contraception. Most results were comparable across all participating countries.

Metrics

17 Record Views

2 citations in Web of Science

Details

Title: Real world utilization of 91 day extended levonorgestrel-containing combined oral contraceptives in Europe: a multinational database study
Creators: Sigal Kaplan
Massoud Toussi
Alison Evans
Sandeep Dhanda
Debabrata Roy
Amir Lass
Publication Details: Current medical research and opinion, v 37(3)
Resource Type: Journal article
Language: English
Academic Unit: Epidemiology and Biostatistics
Web of Science ID: WOS:000616860900001
Scopus ID: 2-s2.0-85101073742
Other Identifier: 991021811635904721

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types: Industry collaboration; Domestic collaboration; International collaboration
Web of Science research areas: Medicine, Research & Experimental